Farringdon Capital’s Evolent Health EVH Stock Holding History

Farringdon Capital’s Portfolio EVH Stock Details EVH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-13,248	Closed	-$112K	–	489
2025 Q3	$112K	Buy	+13,248	New	+$129K	0.03%	424

Other funds holding EVH

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Rubicon Founders Nashville, Tennessee $138M AUM 61.96% 1-Year Est. Return

Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Farringdon Capital's EVH Position: Q4 2025 in Review

Farringdon Capital sold out of Evolent Health (EVH) in Q4 2025, closing a stake of 13,248 shares — an estimated $112K sold.

Farringdon Capital first reported a position in EVH in Q3 2025 and held it in 1 quarter. The position peaked at $112K in Q3 2025. 215 funds tracked by Wall St. Rank hold EVH as of Q4 2025.

Farringdon Capital reported no remaining Evolent Health position as of Q4 2025 after selling out during the quarter.
Farringdon Capital sold 13,248 Evolent Health shares in Q4 2025, an estimated $112K.
Farringdon Capital first reported a position in Evolent Health in Q3 2025 and held it in 1 quarter.
Farringdon Capital's Evolent Health position peaked at $112K in Q3 2025.
215 funds tracked by Wall St. Rank held Evolent Health as of Q4 2025.

Based on Farringdon Capital's 13F filing for Q4 2025, filed 17 Feb 2026.